The battle to attract biotech listings rages on

Author: Karry Lai | Published: 21 Jan 2020

Since the Hong Kong Stock Exchange (HKEX) made changes to its listing rules in April 2018 in a direct attempt to appeal to biotech companies, the jurisdiction has attracted 12 biotech companies to list in Hong Kong SAR.

It’s a good start, but HKEX still has a lot of work to do to catch up to the Nasdaq, and Shanghai’s new technology and innovation board is equally a threat. Market participants in Hong Kong SAR point to a number of areas in which the jurisdiction could improve to better attract listings and the considerations that companies make when choosing whether and where to list. But at the end of the day, when compared with the Nasdaq, HKEX still lacks in market depth, which will take a considerable amount of time to build up.

US remains top IPO destination despite competition

Biotech companies differ from others in that their path...